These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35692512)

  • 1. Repurposing FDA approved drugs as possible anti-SARS-CoV-2 medications using ligand-based computational approaches: sum of ranking difference-based model selection.
    De P; Kumar V; Kar S; Roy K; Leszczynski J
    Struct Chem; 2022; 33(5):1741-1753. PubMed ID: 35692512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction reliability of QSAR models: an overview of various validation tools.
    De P; Kar S; Ambure P; Roy K
    Arch Toxicol; 2022 May; 96(5):1279-1295. PubMed ID: 35267067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quick and efficient quantitative predictions of androgen receptor binding affinity for screening Endocrine Disruptor Chemicals using 2D-QSAR and Chemical Read-Across.
    Banerjee A; De P; Kumar V; Kar S; Roy K
    Chemosphere; 2022 Dec; 309(Pt 1):136579. PubMed ID: 36174732
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined deep learning and molecular docking simulations approach identifies potentially effective FDA approved drugs for repurposing against SARS-CoV-2.
    Anwaar MU; Adnan F; Abro A; Khan RA; Rehman AU; Osama M; Rainville C; Kumar S; Sterner DE; Javed S; Jamal SB; Baig A; Shabbir MR; Ahsan W; Butt TR; Assir MZ
    Comput Biol Med; 2022 Feb; 141():105049. PubMed ID: 34823857
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Gurung AB
    Gene Rep; 2020 Dec; 21():100860. PubMed ID: 32875166
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturbation-based virtual screening of existing drugs.
    Li Z; Li X; Huang YY; Wu Y; Liu R; Zhou L; Lin Y; Wu D; Zhang L; Liu H; Xu X; Yu K; Zhang Y; Cui J; Zhan CG; Wang X; Luo HB
    Proc Natl Acad Sci U S A; 2020 Nov; 117(44):27381-27387. PubMed ID: 33051297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrated computational approach towards repurposing of antimalarial drug against SARS-CoV-2 main protease.
    Gogoi N; Chowdhury P; Goswami AK; Das A; Chetia D; Gogoi B
    Struct Chem; 2022; 33(5):1409-1422. PubMed ID: 35669793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computational screening of FDA approved drugs of fungal origin that may interfere with SARS-CoV-2 spike protein activation, viral RNA replication, and post-translational modification: a multiple target approach.
    Singh R; Gautam A; Chandel S; Sharma V; Ghosh A; Dey D; Roy S; Ravichandiran V; Ghosh D
    In Silico Pharmacol; 2021; 9(1):27. PubMed ID: 33842191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repurposing drugs against the main protease of SARS-CoV-2: mechanism-based insights supported by available laboratory and clinical data.
    Chakraborti S; Bheemireddy S; Srinivasan N
    Mol Omics; 2020 Oct; 16(5):474-491. PubMed ID: 32696772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glecaprevir and Maraviroc are high-affinity inhibitors of SARS-CoV-2 main protease: possible implication in COVID-19 therapy.
    Shamsi A; Mohammad T; Anwar S; AlAjmi MF; Hussain A; Rehman MT; Islam A; Hassan MI
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32441299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2.
    Biering SB; Van Dis E; Wehri E; Yamashiro LH; Nguyenla X; Dugast-Darzacq C; Graham TGW; Stroumza JR; Golovkine GR; Roberts AW; Fines DM; Spradlin JN; Ward CC; Bajaj T; Dovala D; Schulze-Gamen U; Bajaj R; Fox DM; Ott M; Murthy N; Nomura DK; Schaletzky J; Stanley SA
    ACS Infect Dis; 2021 Aug; 7(8):2337-2351. PubMed ID: 34129317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hybrid drug-screening strategy identifies potential SARS-CoV-2 cell-entry inhibitors targeting human transmembrane serine protease.
    Feng Y; Cheng X; Wu S; Mani Saravanan K; Liu W
    Struct Chem; 2022; 33(5):1503-1515. PubMed ID: 35571866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of SARS-CoV-2 inhibitors through phylogenetics and drug repurposing.
    Mishra A; Mulpuru V; Mishra N
    Struct Chem; 2022; 33(5):1789-1797. PubMed ID: 35910782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TAT-peptide conjugated repurposing drug against SARS-CoV-2 main protease (3CLpro): Potential therapeutic intervention to combat COVID-19.
    Ansari MA; Jamal QMS; Rehman S; Almatroudi A; Alzohairy MA; Alomary MN; Tripathi T; Alharbi AH; Adil SF; Khan M; Shaheer Malik M
    Arab J Chem; 2020 Nov; 13(11):8069-8079. PubMed ID: 34909057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. RETRACTED ARTICLE: Discovery of (
    Rabie AM
    Chem Zvesti; 2021; 75(9):4669-4685. PubMed ID: 34025012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Silico Screening and Testing of FDA-Approved Small Molecules to Block SARS-CoV-2 Entry to the Host Cell by Inhibiting Spike Protein Cleavage.
    Ozdemir ES; Le HH; Yildirim A; Ranganathan SV
    Viruses; 2022 May; 14(6):. PubMed ID: 35746605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and
    Banerjee S; Yadav S; Banerjee S; Fakayode SO; Parvathareddy J; Reichard W; Surendranathan S; Mahmud F; Whatcott R; Thammathong J; Meibohm B; Miller DD; Jonsson CB; Dubey KD
    J Chem Inf Model; 2021 Nov; 61(11):5469-5483. PubMed ID: 34666487
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-Targeted Approaches and Drug Repurposing Reveal Possible SARS-CoV-2 Inhibitors.
    Alanazi KM; Farah MA; Hor YY
    Vaccines (Basel); 2021 Dec; 10(1):. PubMed ID: 35062685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.